- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
28 czerwca 2016 zaktualizowane przez: Bristol-Myers Squibb
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Przegląd badań
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
248
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
Gauteng
-
Johannesburg, Gauteng, Afryka Południowa, 2199
- Local Institution
-
-
Western Cape
-
Cape Town, Western Cape, Afryka Południowa, 7570
- Local Institution
-
-
-
-
-
Buenos Aires, Argentyna, CP1280AEB
- Local Institution
-
-
-
-
-
Wels, Austria, A-4600
- Local Institution
-
Wien, Austria, 1090
- Local Institution
-
-
-
-
-
Brussels, Belgia, 1090
- Local Institution
-
Brussels, Belgia, 1070
- Local Institution
-
Bruxelles, Belgia, 1200
- Local Institution
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazylia, 90610
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brazylia, 90050
- Local Institution
-
-
Sao Paulo
-
Jau, Sao Paulo, Brazylia, 17210
- Local Institution
-
-
-
-
-
Aarhus C, Dania, 8000
- Local Institution
-
-
-
-
-
St. Petersburg, Federacja Rosyjska, 191104
- Local Institution
-
Stavropol, Federacja Rosyjska, 355047
- Local Institution
-
Voronezh, Federacja Rosyjska, 394000
- Local Institution
-
-
-
-
-
Brest, Francja, 29200
- Local Institution
-
Lyon Cedex 08, Francja, 69373
- Local Institution
-
Paris, Francja, 75010
- Local Institution
-
Vandoeuvre Les Nancy, Francja, 54511
- Local Institution
-
-
-
-
-
Malaga, Hiszpania, 29010
- Local Institution
-
Valencia, Hiszpania, 46009
- Local Institution
-
-
-
-
-
Jerusalem, Izrael, 91120
- Local Institution
-
Tel-Aviv, Izrael, 64239
- Local Institution
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N2
- Local Institution
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Local Institution
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- Local Institution
-
-
-
-
-
Berlin, Niemcy, D-12200
- Local Institution
-
Heidelberg, Niemcy, 69120
- Local Institution
-
Kiel, Niemcy, D-24105
- Local Institution
-
-
-
-
-
Oslo, Norwegia, 0310
- Local Institution
-
-
-
-
-
Lodz, Polska, 90553
- Local Institution
-
Poznan, Polska, 61-866
- Local Institution
-
Wroclaw, Polska, 51-124
- Local Institution
-
-
-
-
-
Olomouc, Republika Czeska, 775 20
- Local Institution
-
-
-
-
Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85719
- University of Arizona Cancer Center
-
-
California
-
Laverne, California, Stany Zjednoczone, 91750
- Wilshire Oncology Medical Group Inc
-
Los Angeles, California, Stany Zjednoczone, 90033
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Stany Zjednoczone, 90025
- The Angeles Clinic & Research Inst.
-
San Francisco, California, Stany Zjednoczone, 94115
- San Francisco Oncology Associates
-
-
Connecticut
-
To come, Connecticut, Stany Zjednoczone
- Local Institution
-
-
Florida
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Baptist Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Indiana Oncology Hematology Consultants
-
-
Missouri
-
Saint Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
St Joseph, Missouri, Stany Zjednoczone, 64507
- St Joseph Oncology Inc
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- The Christ Hospital Cancer Center Research
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75230
- Center For Oncology Research & Treatment, P.A.
-
Lubbock, Texas, Stany Zjednoczone, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- University of Washington Medical Center
-
-
-
-
-
Dnepropetrovsk, Ukraina, 49044
- Local Institution
-
-
-
-
-
Genova, Włochy, 16132
- Local Institution
-
Meldola (Fc), Włochy, 47014
- Local Institution
-
Rimini, Włochy, 47900
- Local Institution
-
Siena, Włochy, 53100
- Local Institution
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria
- Diagnosis of advanced melanoma
- Prior treatment in a prespecified prior/parent ipilimumab study
- Men and women 18 years of age and older
First Reinduction:
- No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
- Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
- Received ipilimumab at any dose in a parent study
- Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
- Received ipilimumab at any dose in a closing parent study
- Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
Key Exclusion Criteria
- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
- Primary ocular or mucosal melanoma
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Eksperymentalny: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Eksperymentalny: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Eksperymentalny: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Eksperymentalny: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Eksperymentalny: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Inne nazwy:
|
|
Brak interwencji: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
Ramy czasowe: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related is defined as having certain, probable, possible, or missing relationship to study drug.
An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Survival (OS)
Ramy czasowe: From first dose of study drug in parent study to death or date of last censoring.
|
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death.
If a patient has not died, OS was censored at the time of last contact.
|
From first dose of study drug in parent study to death or date of last censoring.
|
|
Percentage of Participants Surviving at 1, 1.5, and 2 Years
Ramy czasowe: From first dose of study drug in parent study to up to 2 years after reinduction
|
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
|
From first dose of study drug in parent study to up to 2 years after reinduction
|
|
Number of Participants With On-study Immune-related Adverse Events (irAEs)
Ramy czasowe: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related.
These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems).
Patients may have 1 or more events.
|
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
|
Progression-free Survival (PFS)
Ramy czasowe: From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
|
From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Przydatne linki
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 maja 2006
Zakończenie podstawowe (Rzeczywisty)
1 września 2012
Ukończenie studiów (Rzeczywisty)
1 kwietnia 2014
Daty rejestracji na studia
Pierwszy przesłany
9 września 2005
Pierwszy przesłany, który spełnia kryteria kontroli jakości
9 września 2005
Pierwszy wysłany (Oszacować)
13 września 2005
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
27 lipca 2016
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
28 czerwca 2016
Ostatnia weryfikacja
1 czerwca 2016
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według typu histologicznego
- Nowotwory
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Guzy neuroendokrynne
- Nevi i czerniaki
- Czerniak
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwnowotworowe
- Środki przeciwnowotworowe, immunologiczne
- Inhibitory immunologicznego punktu kontrolnego
- Ipilimumab
Inne numery identyfikacyjne badania
- CA184-025
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .